Roivant Sciences Ltd. Common Shares vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Roivant Sciences Ltd. Common Shares trades at $35.44 (market cap $24.72B), while Direxion Daily FTSE China Bull 3x Shares trades at $25.27 (market cap $560.32M). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 44.1× Direxion Daily FTSE China Bull 3x Shares's market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roivant Sciences Ltd. Common Shares for 1 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| ROIV | YINN | |
|---|---|---|
Market Cap | $24.72B | $560.32M |
Volume | 6,279,442 | 1,009,521 |
Sector | Health | Leveraged / Inverse |
52-Week High | $41.81 | $52.69 |
52-Week Low | $16.04 | $21.45 |
Typical Hold Time | 1 Days | 25 Days |
Enterprise Value | $20.99B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
YINN is trading at $25.27, up 7.26% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks disclosed fundamental ratios such as P/E and P/S, and recent news highlights China's economic policies and energy sector dynamics, which may influence its performance. Support is clustered around $23, with resistance at $24.
The outlook remains cautious due to bearish technicals and limited fundamental visibility. Risks include reliance on Chinese economic conditions and potential regulatory changes. Investment opportunities hinge on improved earnings transparency and positive shifts in market sentiment, but current data suggests a neutral to bearish stance for near-term investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →